click enter text
rais estim target price follow
guidanc step high bar last week report fiscal
ep well expect rais ep guidanc
pharma medic result estim
revis guidanc also appear imb signific amount
conservat medic segment second half relat potenti
disrupt on-going recal surgic gown impact kit
could allow outperform guidanc entir warrant
result clearli improv unclear degre core pharma
growth sustain next year continu believ
deliv better earn growth long-term less cash-
constrain post opioid settlement thu deserv higher multipl
ep move target price increas
trade fundament data
upsid target
pharma stronger pharma result attribut primarili gener
program swing tailwind headwind first time sever
quarter segment ebit guidanc improv lsd hsd/ldd
previous exclud renew opioid litig expens see core
growth revis lsd/msd msd see
page detail visibl sustain level growth remain
low sens anoth step-funct improv gener
profit like assum lsd core growth
medic impli second half ebit guidanc medic segment
signific step-down first half indic driven
conservat around potenti disrupt on-going recal surgic
gown impact kit importantli estim reflect
normal level profit whether prove conserv less
relev view earn power valuat
price given inflect trend potenti conservat
also increas target ebit multipl previous
compar respect target
price move
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
cah comment call seem suggest pharma profit go grow y/i fiscal would
leav ytd profit growth requir declin meet full-year guidanc lsd
discuss harder comp given gener program improv start time note impli core
growth note opioid litig expens could higher y/i base cah revis
expect highest level litig expens
assum core growth moder fiscal given low visibl whether current core
profit growth sustain cah guidanc would seem imb modest level growth start
would presum annual next year
page
pharma ebit bridg report opioid litig run-rat ebit ex opioid headwind report ebit ex opioid opioid litig report ebit ebit bridg report opioid litig ny state opioid expens run-rat ebit ex opioid headwind report ebit ex opioid opioid litig report ebit ebit bridg report opioid litig run-rat ebit ex opioid headwind report ebit ex opioid opioid litig report ebit
evolut pharma segment guidanc
segment ebit guidanc improv lsd hsd/ldd previous exclud renew opioid litig
expens see core growth revis lsd/msd msd
exhibit decomposit pharma ebit guidanc driver
gener deflat acceler decemb
first time sever quarter gener program tailwind earn instead headwind
credit compon program sourc sell-sid price volum new launch emphas
contribut red oak sourc jv w/
interestingli gener market track indic rate deflat matur drug pick decemb
chain store appear drive chang theori chain store distributor similar gener drug
acquisit cost given purchas gener togeth consortium
measur y/i price declin matur gener drug decemb novemb
oral drug gener market see matur drug price y/i
decemb novemb
note retail mail channel non-retail primarili provider-bas exclud
iqvia wolf research llc
page
initi guidanc commentrevis guidanc commentcontract largest driver initi guidancecontract unchangedopioid increas expect pharma ebit guidanc hsd/ldd total pharma ebit guidanc lsd
thought medic segment implic
impli second half profit medic segment signific step-down first half indic
driven conservat around potenti disrupt on-going recal surgic gown impact kit
illustr cah profit trend busi potenti conservat shown red
estim approxim ebit
appear quit conserv given cah discuss issu call take compani word
given low visibl
importantli estim reflect normal level profit whether prove conserv
less relev view earn power valuat
exhibit medic segment ebit actual wolf estim
page
ep bridg
exhibit ep ep wr estim
note fiscal year end calcul base ebit margin exampl show posit contribut mean revenu grow
quickli
exhibit ep ep wr estim
note fiscal year end calcul base ebit margin exampl show posit contribut mean revenu grow
quickli
page
page
compani data factset wolf research
page
cardin rel ev ebit rel ev ebit rel ev ebit rel ev ebit ev ebit enterpris debt prefer conv debt unconsolid equiti count rel price dividend rel dividend total rel
page
